Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
03 mai 2017 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at...
Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
27 avr. 2017 07h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled “An Update on Hormonal...
Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
11 avr. 2017 07h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...
Agile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
08 mars 2017 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company today reported financial results for the three months...
Agile Therapeutics to Present at 29th Annual ROTH Conference
01 mars 2017 16h10 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company announced today that its Chief Executive Officer, Al...
Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
14 févr. 2017 16h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics Announces Positive Top-line Phase 3 Results
03 janv. 2017 16h11 HE
|
Agile Therapeutics, Inc.
Resubmission of Twirla® New Drug Application Expected to Address FDA’s Complete Response LetterCompany Plans to Resubmit NDA in First Half of...
Agile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding from New Jersey’s Technology Business Tax Certificate Transfer Program
01 déc. 2016 08h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company announced today that it has received net proceeds of...
Agile Therapeutics Reports Third Quarter 2016 Financial Results and Announces Completion of Subject Visits for Twirla® Phase 3 SECURE Clinical Trial
07 nov. 2016 16h10 HE
|
Agile Therapeutics, Inc.
Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017 Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE...
Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline
12 juil. 2016 16h12 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new...